Authors: Joanna Dyczkowska; Ricardo Luiz Sichel
Addresses: Department of Costing, Management Accounting and Control, Wroclaw University of Economics, Komandorska St. 118/120, 53-345 Wroclaw, Poland ' Center for Legal and Political Sciences, Federal University of the State of Rio de Janeiro, Av. Pasteur, 436 – Urca, Rio de Janeiro, RJ, 22290-240, Brazil
Abstract: Due to quick development of proprietary methodologies, systems or technologies pharmaceuticals and biotechnology industry requires a variety of IPRs protection mechanisms. Going forward, the complex R&D projects and their long-term character impose a necessity of transparency concerning IPRs protection. Stakeholders should not be provided with a misleading impression about the protection breadth, the likelihood of patent grant or the ability of the company to enforce its patent rights. The paper explores and analyses the critical IPRs protection issues disclosed by European biopharmaceutical companies in the narrative parts of their annual reports. These critical issues refer to IPRs protection strategy, risk and mitigation policies, R&D and IPRs regulatory framework, patent portfolio, infringements or litigations, and exclusive rights. The examination of disclosure practices proved that the IPRs protection-related risks and exclusive rights were the most frequently reported areas.
Keywords: biopharmaceutical companies; intellectual property rights; research and development; voluntary disclosure.
International Journal of Intellectual Property Management, 2019 Vol.9 No.3/4, pp.185 - 229
Accepted: 01 Mar 2019
Published online: 14 Oct 2019 *